Crescent Capital BDC (487) Q3 2026 Earnings Report

The call was broadly positive, supported by net investment income above the regular dividend, stable overall portfolio performance, no new nonaccruals, strong platform commitments, substantial liquidity, and announced share repurchase and joint venture initiatives. However, the company continues to face subdued LBO activity, delayed realizations, leverage above its long-term target, a higher watch-list percentage, limited new deployment and ongoing credit-management challenges. The positive operating results and shareholder-support initiatives significantly outweighed the stated challenges.

CCAP expects the unconsolidated joint venture to be completed during the fourth quarter of 2026, seeded with approximately $150 million of performing first lien assets, with CCAP committing $30 million of equity and the joint venture equity partner contributing $30 million, alongside an ABL facility; the company is targeting a low to mid-teens ROE, expects the joint venture to be accretive to gross yield, and expects its total size to be around $150 million to $200 million, or roughly 2% of the portfolio, going forward. CCAP expects to use JV proceeds to reduce leverage to its target range and fund its $50 million share repurchase program, while Sun Life will purchase up to an additional $25 million of shares at certain thresholds below net asset value per share; pending portfolio realizations and the joint venture are expected to bring net leverage to within the target range by year-end. The company is not contemplating any further JVs in the near term, expects the JV to be a permanent part of the CCAP portfolio in the near term and to replenish assets as the initial seed portfolio rotates, and expects a pickup in activity going into 2027.